Plecanatide | CAS#467426-54-6 | Uroguanylin analog

MedKoo Cat#: 330236 | Name: Plecanatide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).

Chemical Structure

Plecanatide

CAS#467426-54-6 (free base)

Theoretical Analysis

MedKoo Cat#: 330236

Name: Plecanatide

CAS#: 467426-54-6 (free base)

Chemical Formula: C65H104N18O26S4

Exact Mass: 1680.6252

Molecular Weight: 1681.89

Elemental Analysis: C, 46.42; H, 6.23; N, 14.99; O, 24.73; S, 7.62

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 450.00	2 Weeks
10mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1075732-84-1 (acetate) 467426-54-6 (free base)

Synonym

Plecanatide; SP-304; SP 304; SP304; Trulance

IUPAC/Chemical Name

L-asparaginyl-L-alpha-aspartyl-L-alpha-glutamyl-L-cysteinyl-L-alpha-Glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-leucine cyclic (4→12),(7→15)-bis(disulfide)

InChi Key

NSPHQWLKCGGCQR-DLJDZFDSSA-N

InChi Code

InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1

SMILES Code

CC(C)C[C@H](NC([C@H]1NC(CNC([C@@H](NC([C@H]2NC([C@H](C)NC([C@@H](NC([C@H](CC(N)=O)NC([C@@H](NC([C@H](CSSC1)NC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](CSSC2)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@@H](N)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)C(C)C)=O)=O)C(C)C)=O)=O)=O)[C@@H](C)O)=O)=O)=O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Plecanatide (brand name Trulance), is a drug approved by the FDA for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. Plecanatide is an agonist of guanylate cyclase-C. Plecanatide increases intestinal transit and fluid through a buildup of cGMP. Amino acid sequence of Plecanatide H-Asn1-Asp2-Glu3-Cys4-Glu5-Leu6-Cys7-Val8-Asn9-Val10-Ala11-Cys12-Thr13-Gly14-Cys15-Leu16-OH Elevation of extracellular cGMP has been associated with a decrease in the activity of pain-sensing nerves in animal models of visceral pain. Elevation of intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, plecanatide has been shown to increase fluid secretion into the gastrointestinal (GI) tract, accelerate intestinal transit, and cause changes in stool consistency.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,681.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548762/ PubMed PMID: 31644071. 2: Bassotti G, Usai Satta P, Bellini M. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1019-1026. doi: 10.1080/17512433.2019.1670057. Epub 2019 Oct 1. Review. PubMed PMID: 31575291. 3: Sharma A, Herekar AA, Bhagatwala J, Rao SS. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. Clin Exp Gastroenterol. 2019 Jan 22;12:31-36. doi: 10.2147/CEG.S145668. eCollection 2019. Review. PubMed PMID: 30774407; PubMed Central PMCID: PMC6348976. 4: Miner PB Jr. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation. Drug Saf. 2019 May;42(5):603-615. doi: 10.1007/s40264-018-0781-9. Review. PubMed PMID: 30649746. 5: Love BL. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome. Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11. Review. PubMed PMID: 30550753. 6: Islam BN, Sharman SK, Browning DD. Clinical utility of plecanatide in the treatment of chronic idiopathic constipation. Int J Gen Med. 2018 Aug 10;11:323-330. doi: 10.2147/IJGM.S125051. eCollection 2018. Review. PubMed PMID: 30127634; PubMed Central PMCID: PMC6089121. 7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK513065/ PubMed PMID: 30000995. 8: Martinez de Andino N. Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. J Am Assoc Nurse Pract. 2018 Jul;30(7):412-420. doi: 10.1097/JXX.0000000000000090. Review. PubMed PMID: 29979299. 9: Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018 Jun 8;11:1756284818777945. doi: 10.1177/1756284818777945. eCollection 2018. Review. PubMed PMID: 29942351; PubMed Central PMCID: PMC6009086. 10: Miner PB Jr. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2018 Feb;19(2):177-183. doi: 10.1080/14656566.2018.1427733. Epub 2018 Jan 29. Review. PubMed PMID: 29376436. 11: Al-Salama ZT, Syed YY. Plecanatide: First Global Approval. Drugs. 2017 Apr;77(5):593-598. doi: 10.1007/s40265-017-0718-0. Review. PubMed PMID: 28255961.